ArticleBioengineering (Basel, Switzerland)2025
Explainable Computational Imaging for Precision Oncology: An Interpretable Deep Learning Framework for Bladder Cancer Histopathology Diagnosis.
Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Time-Frequency Respiratory Impedance Maps Enable Within-Breath Deep Learning for Small Airway Dysfunction Identification.Bioengineering (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer represents a significant health problem worldwide, with it being a major cause of death and characterized by frequent recurrences. Effective treatment hinges on early and accurate diagnosis; however, traditional methods are invasive, time-consuming, and subjective. In this research, we propose a transparent deep learning model based on the YOLOv11 structure to not only enhance lesion detection but also give the visual support of the model's predictions. Five versions of YOLOv11-nano, small, medium, large, and extra large-were trained and tested by us on a comprehensive dataset of hematoxylin and eosin-stained histopathology slides with the inflammation, urothelial cell carcinoma (UCC), and invalid tissue categories. The YOLOv11-large variant turned out to be the best-performing model at the forefront of technology, with an accuracy of 97.09%, precision and recall of 95.47% each, and balanced accuracy of 96.60%. Besides the precision-recall curves (AUPRC: inflammation = 0.935, invalid = 0.852, UCC = 0.958), ROC-AUC curves (overall AUC = 0.972) and risk-coverage analysis (AUC = 0.994) were also used for detailed assessment of the model to confirm its steadiness and trustworthiness. The confusion matrix displayed the highest true positive rates in all classes and a few misclassifications, which mainly happened between inflammation and invalid samples, indicating a possible morphological overlap. Moreover, as supported by a low Expected Calibration Error (ECE), the model was in great calibration. YOLOv11 reaches higher performance while still being computationally efficient by incorporating advanced architectural features like the C3k2 block and C2PSA spatial attention module. This is a step towards the realization of the AI-assisted bladder cancer diagnostic system that is not only reliable and transparent but also scalable, presented in this work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.